Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

One Step Toward Stopping The New Tuberculosis


Developements to Watch

ONE STEP TOWARD STOPPING THE NEW TUBERCULOSIS

ike a movie monster that refuses to die, tuberculosis is making a comeback. Scientists thought they had brought the disease under control with antibiotics in the 1950s and '60s. But since then, the tuberculosis-causing bacterium has evolved into drug-resistant strains, so cases are soaring.

Medicine is poised for a counterattack, however. Working with colleagues in France, scientists at London's Hammersmith Hospital have figured out how the tuberculosis bacterium evades drugs. The microbe's secret, the researchers reported in the Aug. 13 issue of Nature, is a single inoperative gene. This gene normally activates an enzyme that alters an antibiotic, changing it from harmless to deadly. Without the enzyme, the drug remains harmless.

The gene sleuthing opens the door for new drugs. One solution is simply duplicating the enzyme's effect by administering a converted form of the antibiotic rather than the original drug. Another is using the new information to figure out how the enzyme-altered chemicals actually kill microbes, then designing drugs that attack the same targets. The new discovery, concludes public health expert Dr. Barry R. Bloom of the Albert Einstein College of Medicine, "offers hope that molecular genetics may be one way to tackle the emerging problem of drug-resistant tuberculosis."EDITED BY EMILY T. SMITH


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus